Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Reinholz, B. Getz, L. Pederson, Emily Sanders, M. Subramaniam, J. Ingle, T. Spelsberg (2000)
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.Cancer research, 60 21
J. Body, A. Lortholary, G. Romieu, A. Vigneron, J. Ford (1999)
A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 14
J. Berenson, R. Vescio, Lee Rosen, Joseph VonTeichert, Margie Woo, R. Swift, Allison Savage, E. Givant, Mieke Hupkes, Harold Harvey, Allan Lipton (2001)
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 3
R.E. Coleman, L.S. Rosen, D. Gordon (2002)
Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis [abstract 355]Breast Cancer Res Treat, 76
O. Fromigué, J. Body (2002)
Bisphosphonates influence the proliferation and the maturation of normal human osteoblastsJournal of Endocrinological Investigation, 25
S. Gordon, M. Helfrich, H. Sati, M. Greaves, S. Ralston, D. Culligan, R. Soutar, M. Rogers (2002)
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myelomaBritish Journal of Haematology, 119
L. Rosen, D.H. Gordon, W. Dugan (2002)
Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion [abtract 629]. 27th European Society for Medical Oncology Congress; 2002 Oct 18–22; NiceAnn Oncol, 13
S. Senaratne, J. Mansi, K. Colston (2002)
The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cellsBritish Journal of Cancer, 86
S. Derenne, M. Amiot, S. Barillé, M. Collette, N. Robillard, P. Berthaud, J. Harousseau, R. Bataille (1999)
Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 14
A. Pataki, K. Müller, J. Green, Y. Ma, Qing Li, W. Jee (1997)
Effects of short‐term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatmentThe Anatomical Record, 249
J. Green, K. Müller, K. Jaeggi (1994)
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 9
F. Coxon, M. Helfrich, R. Hof, S. Sebti, S. Ralston, A. Hamilton, M. Rogers (2000)
Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI‐298Journal of Bone and Mineral Research, 15
SP Jagdev, R. Coleman, CM Shipman, A. Rostami-H, P. Croucher (2001)
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelBritish Journal of Cancer, 84
P. Major, A. Lortholary, J. Hon, E. Abdi, G. Mills, H. Menssen, F. Yunus, R. Bell, J. Body, E. Quebe‐Fehling, J. Seaman (2001)
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
J. Berenson, R. Vescio, K. Henick, C. Nishikubo, M. Rettig, R. Swift, Francisco Conde, Joseph Teichert (2001)
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone diseaseCancer, 91
O. Fromigué, L. Lagneaux, J. Body (2000)
Bisphosphonates Induce Breast Cancer Cell Death In VitroJournal of Bone and Mineral Research, 15
L. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, J. Mackey, J. Apffelstaedt, M. Hussein, R. Coleman, D. Reitsma, J. Seaman, Bee Chen, Yvonne Ambros (2001)
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.Cancer journal, 7 5
J. Berenson, L. Rosen, A. Howell, Lester Porter, R. Coleman, W. Morley, R. Dreicer, S. Kuross, A. Lipton, J. Seaman (2001)
Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastasesCancer, 91
L. Witters, M. Javeed, J. Crispino, Jonathan Green, J. Seaman, D. Reitsma, T. Kamal, L. Engle, V. Chinchilli, A. Lipton (2001)
Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitorEuropean Journal of Cancer, 37
B. Garssen (2002)
Psycho-oncology and cancer: linking psychosocial factors with cancer development.Annals of oncology : official journal of the European Society for Medical Oncology, 13 Suppl 4
F. Saad, D.M. Gleason, R. Murray (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Zoledronic Acid Prostate Cancer Study GroupJ Natl Cancer Inst, 94
E. Corey, L.G. Brown, J.E. Quinn (2001)
Effects of zoledronic acid on prostate cancer in vitro and in vivo [abstract 1148 plus poster]. 92nd Annual Scientific Meeting of the American Association for Cancer Researsh; 2001 Mar 24–28; New Orleans, (LA)Proc Am Assoc Cancer Res, 42
F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. Chin, J. Vinholes, J. Goas, Bee Chen (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.Journal of the National Cancer Institute, 94 19
A. Aparicio, A. Gardner, Y. Tu, A. Savage, J. Berenson, A. Lichtenstein (1998)
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonatesLeukemia, 12
Carol Evans, Isobel Braidman (1994)
Effects of two novel bisphosphonates on bone cells in vitro.Bone and mineral, 26 2
J. Dunford, K. Thompson, F. Coxon, S. Luckman, F. Hahn, C. Poulter, F. Ebetino, M. Rogers (2001)
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.The Journal of pharmacology and experimental therapeutics, 296 2
L. Rosen, D. Gordon, S. Tchekmedyian (2001)
Zometa significantly increased the median time to first skeletal related event (SRE) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumours (OST)Lung Cancer, 34
K.P. Weinfurt, Y. Li, L.D. Castel (2002)
The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer [abstract 662]. 27th European Society for Medical Oncology Congress; 2002 Oct 18–22; NiceAnn Oncol, 13
J.R. Berenson, L.S. Rosen, A. Howell (2001)
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized doseresponse studyCancer, 91
Zoledronic acid (Zometa®) is an effective inhibitor of osteoclast-mediated bone resorption. Zoledronic acid demonstrated efficacy in the reduction of skeletal-related events (SREs) in patients with multiple myeloma or bone metastases secondary to breast cancer, prostate cancer or other solid tumors, or hypercalcemia of malignancy.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.